180N - Tromsø

Towards our goals, a consortium in preclinical research experts between Bergen, Tromsø and Trondheim will be established. Radiopharmaceuticals will be tailored to target tumor specific markers and immune cells participating in the tumor microenvironment of glioblastoma (GB), lung and breast cancer. Strategies for designing and radiolabeling the compounds will be coordinated by the Bergen PET radiotracer development center application. Activities in this project will be multidisciplinary and developed at all three sites. Thus, a close cooperation network in the fields of tracer development, pharmacology, chemistry, (radiation) oncology, (radiation) biology, nuclear medicine, immunology, drug development and machine learning (ML) will be established. To support the theranostic success, conventional therapies such as chemo-, immune- and external radiation therapy will be used as complementary treatments to improve the personalized cancer care in the clinics. In addition, immune-markers are introduced as imaging agents and assessed for optimal selection of therapeutic interventions and treatments. Animal models of cancer will form the basis to investigate the performance of the developed radioligands and to evaluate the anti-tumoral effects of different treatment combinations. Concurrently, to improve quantitative measures and to monitor therapy-induced changes, novel ML methods will be developed and applied to the imaging data. This will be further developed as a clinical tool to facilitate treatment selection and monitoring in routine clinical application.This scientific consortium, with its unique infrastructure and merged experience, will push forward the development of imaging agents, radiotheranostics and patient-specific nuclear therapies. We believe, with the aforementioned efforts, that the treatment burden will be reduced and the patience care significantly improved.